1-5 of 5
Arif Hussain
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J. Hsieh, Arif Hussain, Ulka Vaishampayan, Sandy Liu, Steven McCune, Vijay Patel, Montaser Shaheen, Johanna Bendell, Alice C. Fan, Benjamin A. Gartrell, Oscar B. Goodman, Jr, Petros G. Nikolinakos, Arash Rezazadeh Kalebasty, Yousef Zakharia, Zhentao Zhang, Hema Parmar, Lalith Akella, Keith Orford, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3248–3255.
https://doi.org/10.1158/1078-0432.CCR-22-0061
Published: 02 August 2022
View article titled, Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Open the PDF for Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial in another window
Includes: Supplementary data
Journal Articles

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

Andrea Loehr, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H. Bryce, Ray McDermott, Brieuc Sautois, Nicholas J. Vogelzang, Richard M. Bambury, Eric Voog, Jingsong Zhang, Josep M. Piulats, Arif Hussain, Charles J. Ryan, Axel S. Merseburger, Gedske Daugaard, Axel Heidenreich, Karim Fizazi, Celestia S. Higano, Laurence E. Krieger, Cora N. Sternberg, Simon P. Watkins, Darrin Despain, Andrew D. Simmons, Melanie Dowson, Tony Golsorkhi, Simon Chowdhury, Wassim Abida
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6677–6686.
https://doi.org/10.1158/1078-0432.CCR-21-2199
Published: 15 December 2021
View article titled, Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
Open the PDF for Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study in another window
Includes: Supplementary data
Journal Articles

Divergent Effects of Castration on Prostate Cancer in TRAMP Mice: Possible Implications for Therapy

Yao Tang, Linbo Wang, Olga Goloubeva, Mohammad Afnan Khan, Bin Zhang, Arif Hussain
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (10): 2936–2943.
https://doi.org/10.1158/1078-0432.CCR-07-4925
Published: 15 May 2008
View article titled, Divergent Effects of Castration on Prostate Cancer in TRAMP Mice: Possible Implications for Therapy
Open the PDF for Divergent Effects of Castration on Prostate Cancer in TRAMP Mice: Possible Implications for Therapy in another window
Journal Articles

Docetaxel Followed by Castration Improves Outcomes in LNCaP Prostate Cancer–Bearing Severe Combined Immunodeficient Mice

Yao Tang, Mohammad A. Khan, Olga Goloubeva, Dong I. Lee, Danijela Jelovac, Angela M. Brodie, Arif Hussain
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (1): 169–174.
https://doi.org/10.1158/1078-0432.CCR-05-1388
Published: 05 January 2006
View article titled, Docetaxel Followed by Castration Improves Outcomes in LNCaP Prostate Cancer–Bearing Severe Combined Immunodeficient Mice
Open the PDF for Docetaxel Followed by Castration Improves Outcomes in LNCaP Prostate Cancer–Bearing Severe Combined Immunodeficient Mice in another window
Journal Articles

A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma

Nancy A. Dawson, Chuanfo Guo, Richard Zak, Brenda Dorsey, Jeanne Smoot, Jade Wong, Arif Hussain
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (23): 7812–7819.
https://doi.org/10.1158/1078-0432.CCR-04-0310
Published: 07 December 2004
View article titled, A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma
Open the PDF for A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma in another window